MethylGene and Pharmion report preliminary clinical data at the 2007 AACR-NCI-EORTC International Conference

News | 10. 24. 2007

MethylGene Inc. (TSX:MYG) and Pharmion Corporation (NASDAQ:PHRM) today reported preliminary clinical data from the Companies’ MGCD0103 Phase I/II combination trial with Gemzar® (Trial 006). The data were presented in a poster session at the 2007 AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco on October 24th, 2007.